Summer 2027

Technology Intern

Marshall Wace

Marshall Wace

501-1,000 employees

Global provider of alternative investments

No salary listed

London, UK

In Person

Category
Software Engineering (1)
Required Skills
Python
JavaScript
Git

Get referred to Marshall Wace

See people who can refer or advise you

Requirements
  • High-achieving academically.
  • Demonstrated technical, software engineering skills through coursework, previous internships, research, or a passion for technology.
  • Ability to own work end-to-end, identify opportunities for impact through technology, design the solution, build it, and work directly with stakeholders to align engineering efforts with value creation.
  • Strong collaboration and communication skills.
Responsibilities
  • Interns will be given projects that provide real-world engineering experience and drive the business forward.
  • Projects are proposed by tech teams prior to start and interns are assigned to selected projects in pairs reporting to a senior engineer.
  • Interns receive mentorship from managers and participate in seminars, informational sessions with senior leaders, and social events to support professional and technical development and understanding of the finance industry.
  • Interns will work end-to-end on projects, including identifying opportunities for impact, designing, building, and engaging with stakeholders across the firm.
Desired Qualifications
  • Potential to return to the Technology Graduate Programme as a full-time member after completing studies.

Marshall Wace provides alternative investment solutions to clients around the world. It uses a global, integrated team to design and manage a range of investment strategies focused on delivering risk-adjusted returns for institutions and other investors. The firm works to build long-term client relationships based on trust and integrity, and emphasizes continuous improvement and fresh thinking to create proprietary value that benefits clients. Its products are different from traditional funds in their emphasis on alternative strategies and customized, research-driven approaches, aiming to achieve better outcomes through disciplined, differentiated investment methods. The goal is to grow client value by offering thoughtful, proprietary investment strategies that align with clients’ needs and risk tolerances.

Company Size

501-1,000

Company Stage

N/A

Total Funding

$8.9B

Headquarters

London, United Kingdom

Founded

1997

Get referred to Marshall Wace

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Reuters reported positive 2025 performance in Eureka and Market Neutral Tops.
  • 2026 recruiting in oil and credit expands Marshall Wace into richer, volatile markets.
  • 2026 backing of Draig Therapeutics and Ray Therapeutics strengthens private-market sourcing.

What critics are saying

  • August 6, 2026, Marshall Wace disclosed a 1.19% net short in Alstom.
  • Alpha Plus depends on expensive star traders; one bad hiring cycle destroys edge.
  • Citadel, Millennium, and Balyasny compress returns quickly if Marshall Wace’s signals commoditize.

What makes Marshall Wace unique

  • Marshall Wace’s TOPS and Alpha Plus system converts external research into tradable signals.
  • Paul Marshall and Ian Wace still run a $70B-plus, multi-strategy hedge-fund platform.
  • February 2026 hires Andrew Dodson, Chet Johal, and Alexis Wagener deepen sector coverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Social Events

Company News

eFinancialCareers
Aug 12th, 2026
Morning Coffee: Intense times at the hedge fund with employee pictures on the wall. Another reason to work for Jane Street in Hong Kong.

Morning Coffee: Intense times at the hedge fund with employee pictures on the wall. Another reason to work for Jane Street in Hong Kong. 44 minutes ago As the wisdom of motivational posters might have it, the culture of a financial institution is a bit like a teabag. You never know how strong it really is until it's in hot water. When everything is going well, lots of companies are keen to about their unique collaborative and collegiate environment. It's easy to get along when everyone's making money. But more troubled times often make the fault lines extremely obvious. And it seems that hedge fund Marshall Wace, particularly in its credit team, might currently be going through those kinds of times when the flavour seeps out. Marshall Wace has always tried to have a slightly different culture from the typical "pod shop". More collegiate, less aggressive, less... American? Paul Marshall, the co-founder, has pointed to its unusually high average employment duration and culture of cooperation and teamwork rather than eating what you kill and quickly cutting underperformers. His concern with creating the right atmosphere goes right down to taking a personal interest in the interior design of global offices, including portraits on the walls of valued employees in the style of a British pub celebrating its regulars. The trouble is that MW has historically been dominated by its market leading long/short equities franchise, and so when it wanted to build up other asset classes and strategies, that meant hiring people from outside. And new hires often come with their own culture and habits; it's one of the best-known problems in the industry that it's difficult to maintain your culture during a period of rapid growth. Adding to the problems, when MW hired Dan Schatz from Citadel to be the head of credit, Citadel got very angry and lawyered up. Lawsuits are, famously, a massive sink for management time and effort that could be better spent elsewhere; whatever your problems are, a bit of litigation will always make them worse. Just at the time when the credit team needed to be concentrating on developing a strong culture and building relationships, they had this unwelcome distraction. And Murphy's Law dictates that just when it would be really helpful to have a good run of luck in the market, the opposite tends to happen. Performance figures aren't separately disclosed for the main credit strategies, but it might be assumed from the Alpha Plus fund to which they contribute that things haven't been stellar. The end result seems to have been a number of departures from the credit unit over the last couple of years. Of course, these aren't unique issues for Marshall Wace; everyone in finance will go through some periods of adversity, and managing the teething troubles of rapid growth is the whole business of multistrategy investing. It might even be argued that tough times are what build a culture, as well as challenging it. When things stabilise at Marshall Wace, everyone on the credit desk will at least know how their colleagues react when the chips are down. That's actually quite useful. Marshall Wace declined to comment. Elsewhere, some very good news for asset managers in Hong Kong. It seems that they may also benefit from a planned change to the tax law which would effectively replicate the "carried interest loophole" beloved of private equity fund managers. The local tax authorities have made it clear that "The scope of the proposed enhanced tax concessions for funds and carried interest is not confined to particular types of funds or asset managers. Rather, eligibility is dependent on whether the relevant conditions and requirements are met". In plain English, that means that employees will benefit from it as long as they are getting a contractual share of the fund's profits, rather than a discretionary bonus. Which means that there might be some quite difficult decisions to make. Lots of firms, including some very big hedge funds, try to incorporate some element of discretionary payment into their employees' compensation, in order to encourage things like teamwork, management development and good compliance habits. But if this makes a big tax difference, the employees will be very resistant. Firms like Jane Street and Citadel are already likely to be on the right side of that line, but many other asset managers and family offices might end up deciding that although they don't like formula-driven compensation, they can't afford not to give it. Meanwhile... Driss Haj Khalifa, formerly head of euro swaps at Bank of America in Paris, has gone to Susquehanna in London. Lots of sell-side traders seem to have made this move to macro and multistrategy hedge funds in the last year. (Financial News) It's going to be a bumpy few years for the hard working men and women in investment banking HR in the UK. The cap on compensation at employment tribunals is going to be removed, and the minimum period of employment before someone can bring one will be shortened from two years to six months. At the same time, stricter rules on the duty to prevent sexual harassment at work are likely to be translated into non-financial conduct regulations. (The Banker) "Who needs income when you have wealth?" The strong performance of the stock market has had an unexpected effect - boomers are finding that they have enough savings to take early retirement. (WSJ) Because there are so few ECM deals in their domestic market, London law firms are having to provide secondments to Asia and Europe for their junior staff so that they don't lose their expertise. (Financial News) Most people react to a colleague showing up with a holdall of sweaty gym gear simply by complaining or making sarcastic remarks. Former Citadel trader Maria Cabral Menezes saw it as a possible opportunity to quit and launch a business selling "dry shampoo for clothes". (Business Insider) Someone is suing Kalshi for launching prediction markets on flight cancellations, pointing out that it is almost certainly going to lead to someone doing something stupid or dangerous in order to benefit their trading book. (WSJ) Follow me on X. Follow me on LinkedIn. Have a confidential story, tip, or comment you'd like to share? Contact: +44 7537 182250 (SMS, Whatsapp or voicemail). Telegram: @SarahButcher. Signal: sarahbutcher.22 Click here to fill in our anonymous form, or email [email protected]. Bear with us if you leave a comment at the bottom of this article: comments are moderated intermittently by human beings. Sometimes these humans might be asleep, or away from their desks, so it may take a while for your comment to appear. You must take sole responsibility for comments you post on this site. We will take reasonable steps to weed out anything that we consider to be offensive or inappropriate. The essential daily roundup of news and analysis read by everyone from senior bankers and traders to new recruits. Boost your career. Find thousands of job opportunities by signing up to eFinancialCareers today. Top Articles

GlobeNewswire
Jul 29th, 2026
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS

Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class...

pharmaphorum
Jul 17th, 2026
Radiopharma firm AdvanCell raises $315m, and other financings.

Radiopharma firm AdvanCell raises $315m, and other financings. In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million Series D that swells its coffers as it moves its lead prostate cancer therapy into phase 3 testing. The oversubscribed financing, led by Ally Bridge Group and Alpha Wave, is earmarked for the continued development of ADVC001 - a PSMA-targeted radioligand therapy based on lead-212 that is in a phase 2 trial for metastatic prostate cancer - and to expand its manufacturing capacity for the isotope. ADVC001 has already delivered encouraging safety and efficacy in the ongoing study, which revealed a 100% overall response rate in patients with evaluable prostate tumours, with no dose-limiting toxicities and toxicity-related treatment discontinuations or dose modifications. The US and Australia-based startup is one of a number of biotechs working on the development of targeted alpha therapies (TATs), which are designed to deliver alpha particle radiation to localised areas of the body. The short range of alpha radiation is thought to limit damage to surrounding non-cancerous tissue. At the moment, Bayer's Xofigo (radium Ra 223 dichloride) is the only approved TAT on the market, used to treat metastatic castration-resistant prostate cancer (CRPC) that has spread to bones but not to other organs, although bone safety issues have seen its sales fall sharply from its height of around €500 million a year. Other biotechs working on TATs include Orano Med, in collaboration with Sanofi and RadioMedix, as well as Perspective Therapeutics, Aktis Oncology, Actinium Pharma, and Akiram Therapeutics. New investors in the round included Bain Capital Life Sciences and Fidelity Management & Research Co, with former backers, including the VC arms of Sanofi and Eli Lilly, also taking part. Other recent financing rounds. Also this week, Welsh biotech Draig Therapeutics completed a Series B, raising $65 million in funding led by Deep Track Capital - with participation from Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences - that will be used to develop its therapies for neuropsychiatric disorders. It comes almost exactly a year after the company emerged from stealth with a $140 million first round. Since then, the company has advanced its lead programme - AMPA receptor potentiator DT-101 - into phase 2 testing as a monotherapy and adjunctive therapy for major depressive disorder (MDD). The Series B was also supported by Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences. In a fourth-round financing, AI drug design specialist Drug Farm of China and the US raised $55 million for its pipeline of drug candidates headed by DF-003, an ALPK1 inhibitor for genetic disease ROSAH syndrome, which is being moved into phase 3 testing after a successful phase 1b study. The funds will also be used to continue the clinical development of DF-006, another ALPK1 inhibitor, for hepatitis B. The financing round was co-led by the Shanghai Pudong Leading Area Investment Centre and the Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise, along with multiple new and existing backers. Staying in the AI arena, China's MindRank AI closed a $52 million Series B, led by a group of institutional and healthcare funds, that will be used for further development of its Molecule Arts Platform (MAP) for drug discovery and design. The company's lead programme, codenamed MDR-001, is an oral small-molecule GLP-1 receptor agonist currently in the phase 3 MOBILE clinical trial in China as a treatment for obesity and type 2 diabetes, having shown encouraging efficacy and a very low treatment discontinuation rate in phase 2b studies. An application to start clinical testing of the drug in the US has also been approved. Finally, Cambridge, UK-based Alchemab Therapeutics has extended its Series A financing with a £25 million ($34 million) investment from the British Business Bank, which is earmarked for building its clinical pipeline and growing its proprietary unique antibody dataset, which attracted a $415 million alliance with Eli Lilly last year focused on the ATLX-1282 candidate. The additional funding brings Alchemab's total first-round backing to £109 million, and the company said it will enable it to grow its antibody database from 500 million to a billion antibody sequences, and also advance further clinical candidates into development. 17 July, 2026

FinanzNachrichten.de
Jul 14th, 2026
Draig Therapeutics raises $65M Series B to advance AMPA receptor modulator for major depressive disorder

Draig Therapeutics has closed an oversubscribed $65 million Series B financing round led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace, British Business Bank, and Jefferson Life Sciences. The clinical-stage biopharmaceutical company will use the proceeds to accelerate development of its pipeline of AMPA and GABAA receptor modulators for neuropsychiatric disorders. The lead programme, DT-101, is an AMPA receptor potentiator targeting major depressive disorder. Two Phase 2 studies are currently ongoing: a global trial evaluating DT-101 as monotherapy and a US study testing it as an adjunct treatment. DT-101 has demonstrated encouraging safety, tolerability, and target engagement data. Draig was co-founded by Cardiff University and SV Health Investors. The company's portfolio also includes backing from Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures, and Schroders Capital.

36Kr Holdings Inc.
Jul 2nd, 2026
Ray Therapeutics raises $125M for late-stage optogenetics therapy to restore vision

Ray Therapeutics, a US clinical-stage biotech company co-founded by optogenetics pioneer Zhuo-Hua Pan and Robinhood CEO Vlad Tenev, has raised $125 million in an oversubscribed Series C round led by Janus Henderson Investors. Adage Capital Management, Franklin Templeton, Invus and Marshall Wace participated, with existing investors including 4BIO Capital and Novo Holdings also contributing. The company is developing optogenetic therapies for degenerative retinal diseases. Its lead candidate, RTx-015, targets retinitis pigmentosa and has received RMAT designation from the FDA and PRIME designation from the EMA. A second programme, RTx-021, focuses on macular diseases including Stargardt disease. The funding will advance RTx-015 through late-stage clinical trials and accelerate RTx-021's development. Ray's technology uses modified light-sensitive proteins to restore vision by reprogramming surviving retinal neurons.